Every Form 4 that Charles River Laboratories International, Inc. (CRL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CRL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRL filings page.
Charles River Laboratories International, Inc. Chairman, President and CEO James C. Foster reported equity transactions in company common stock. On January 30, 2026, he acquired 39,031 shares at $0, reflecting performance share units that vested after meeting performance goals from awards granted on May 26, 2023.
On the same date, he disposed of 14,664 shares at $211.68 per share, leaving 253,677 directly held shares. The filing also reports indirect holdings, including 5,423 shares in a 2024 GRAT, 20,000 shares in a 2025 GRAT, additional trust-held shares, and 10,000 shares held by his spouse.
Charles River Laboratories executive Birgit Girshick reported stock transactions tied to equity awards. On January 30, 2026, she acquired 9,500 shares of common stock at $0, reflecting performance goals achieved under performance share units granted on May 26, 2023. On the same date, 3,061 shares were disposed of at $211.68 under a code "F" transaction, typically used for tax withholding, leaving 26,913 shares held directly. Separately, 45,470 shares are held indirectly in a revocable trust controlled by her, following an exempt transfer under Rule 16a-13.
Charles River Laboratories International, Inc. executive Michael Gunnar Knell, CSVP, CAO and Interim CFO, reported equity-related transactions in company common stock. On January 30, 2026, he acquired 1,668 shares at $0 per share, reflecting performance share units earned from awards granted on May 26, 2023.
On the same date, Knell disposed of 526 shares of common stock at $211.68 per share. After these transactions, he directly held 14,602 shares of Charles River Laboratories common stock.
Charles River Laboratories International executive Mark Mintz, EVP and Chief Information Officer, reported equity compensation activity in company stock. On January 30, 2026, he acquired 1,797 shares of common stock at $0, issued after meeting performance goals from performance share unit awards granted on May 26, 2023. On the same date, 655 shares of common stock were disposed of at $211.68 per share under transaction code F. Following these transactions, Mintz directly owned 7,492 shares of Charles River common stock.
Charles River Laboratories International, Inc. officer Shannon M. Parisotto reported equity award activity in company stock. On January 30, 2026, Parisotto acquired 4,236 shares of common stock at $0 per share following the achievement of performance goals under performance share unit awards originally granted on May 26, 2023.
On the same date, 1,067 shares of common stock were disposed of at $211.68 per share, typically reflecting shares withheld to cover taxes. After these transactions, Parisotto directly held 15,184 shares, and indirectly held 982 shares through a revocable trust and 28,510 shares through Karpathos Investments LLC.
Charles River Laboratories International executive reports small stock sale. Executive Vice President of Corporate Strategy & Development Joseph W. LaPlume sold 400 shares of the company's common stock on 08/22/2025 at a price of $163.72 per share. After this transaction, he directly beneficially owned 23,716 shares of Charles River Laboratories common stock.
Charles River Laboratories (CRL) insider update: Interim CFO Michael G. Knell reported an acquisition of 2,926 shares of common stock at $170.88 on 11/06/2025 (transaction code A), increasing his beneficial ownership to 13,460 shares, held directly.
The filing notes these are restricted stock units with a two-step vesting schedule: 50% vest on November 6, 2026 and the remaining 50% on November 6, 2027.